A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

LESSONS LEARNED: This study is a rare example of effective doses of both targeted agents being both administered and tolerated. This combination should not be used in melanoma. BACKGROUND. Sorafenib and bortezomib affect BCL family member expression. We previously demonstrated that bortezomib augmen...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Sullivan, Ryan J., Ibrahim, Nageatte, Lawrence, Donald P., Aldridge, Julie, Giobbie-Hurder, Anita, Hodi, F. Stephen, Flaherty, Keith T., Conley, Christine, Mier, James W., Atkins, Michael B., McDermott, David F.
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2015
Témata:
Clinical Trial Results
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4571786/
https://ncbi.nlm.nih.gov/pubmed/25986244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0105
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky